Madrid

• Apremilast study in children with active oral ulcers associated with Behçet's Disease Ended recruitment
  2023-503436-40-00 5 2024-11-11 Behcet's disease
• A Clinical Study in which patients with acne vulgaris will receive a new topical drug. The safety and efficacy of the drug will be tested. Ended recruitment
  2023-510339-12-00 5 2024-11-11 acne vulgaris
• A Clinical Study in which patients with acne vulgaris will receive a new topical drug for long term. The safety and efficacy of the drug wil … Ended recruitment
  2023-510342-24-00 5 2024-11-11 Acne vulgaris
• Sasanlimab Treatment As Bladder-Sparing Strategy For Patients With Muscle Invasive Bladder Cancer Ended recruitment
  2024-511358-36-00 4 2024-11-11 Molecularly Categorized Muscle Invasive Bladder Cancer
• Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti- … Ended recruitment
  2024-513540-29-00 5 2024-11-07 Breast Cancer
• A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment with Mirvetuximab Soravtansine in Patients with Rec … Ended recruitment
  2023-505617-24-00 4 2024-11-05 Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression
• GenePHIT: A study to learn more about how well a new gene therapy (AB-1002) works and its safety in participants with congestive heart failu … Ended recruitment
  2024-510581-17-00 4 2024-11-05 Adult subjects with New York Heart Association (NYHA) Class III conges
• Study to Evaluate Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA-4 Study) Ended recruitment
  2023-509301-80-00 5 2024-11-04 Severe hypertriglyceridemia (SHTG)
• Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (MUIR-3 Study) Ended recruitment
  2023-509302-30-00 5 2024-11-04 Hypertriglyceridemia
• A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis Ended recruitment
  2024-510753-10-00 5 2024-11-01 Prurigo Nodularis
• Tuvusertib Combined with Niraparib or Lartesertib in Participants with Epithelial Ovarian Cancer (DDRiver EOC 302) Ended recruitment
  2024-511202-23-00 4 2024-10-31 Epithelial ovarian cancer that progressed on prior PARP inhibitor ther
• A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab compared with treatment withdrawal in … Ended recruitment
  2023-508096-36-00 5 2024-10-30 atopic dermatitis
• A study to continue providing GME751 (a new medicine that is similar to pembrolizumab) to participants who are eligible for pembrolizumab tr … Ended recruitment
  2024-513160-25-00 5 2024-10-30 Melanoma and Non-small-cell lung cancer
• A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Ref … Ended recruitment
  2024-516149-38-00 4 2024-10-29 Hodgkin Lymphoma
• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended recruitment
  2023-508636-61-00 5 2024-10-24 Crohn’s Disease
• SPOTLIGHT 204: A Multicenter, Phase 2b, open-label, non-randomized, clinical trial to evaluate safety, tolerability and preliminary efficacy … Ended recruitment
  2024-511801-51-00 4 2024-10-24 Basal cell carcinoma
• A research study to evaluate the efficacy and safety of cenerimod in subjects suffering from systemic lupus erythematosus Ended recruitment
  2024-515871-37-00 5 2024-10-24 Moderate to severe systemic lupus erythematosus
• A study organ preservation with Custodiol-N solution compared with Custodiol solution in liver trasnplantation Ended recruitment
  2024-518174-13-00 5 2024-10-24 Liver transplantation
• INCA34176-254: A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ru … Ended recruitment
  2022-502168-19-00 4 2024-10-22 chronic graft-versus-host disease
• A Phase 2 Study of Obexelimab in Patients with Systemic Lupus Erythematosus Ended recruitment
  2024-510584-37-00 4 2024-10-22 Systemic Lupus Erythematosus
• A study of safety and tolerability (acceptability of potential side effects) of exidavnemab, at 2 different doses, in patients with Parkinso … Ended recruitment
  2024-511222-30-00 4 2024-10-22 Multiple System Atrophy
• A Phase 3 study to evaluate the Efficacy and Safety of Efgartigimod IV in Patients with Acetylcholine Receptor Binding Antibody Seronegative … Ended recruitment
  2024-511796-15-00 5 2024-10-16 Acetylcholine Receptor Binding Antibody Seronegative Generalized Myast
• A Study of Elafibranor in Adults with Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid Ended recruitment
  2024-510695-20-00 5 2024-10-15 Primary Biliary Cholangitis (PBC)
• A Phase 2a/b study of the efficacy and safety of subcutaneous amlitelimab in adults with non-responsive celiac disease Ended recruitment
  2024-511213-38-00 4 2024-10-15 Coeliac disease

Showing 1,801–1,824 of 3,550 trials